Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues

Claudio Borghi, Francesco Rossi, Enrico Agabiti Rosei, Nicola De Luca, GiovanBattista B. Desideri, Giuseppe Mancia, Paolo Pauletto, Gianfranco Parati, Roberto Pontremoli, Giuseppe Schillaci, Michele Stornello, Giuliano Tocci, Franco Veglio, Agostino Virdis, Massimo Volpe, Pier Luigi Canonico, Giuseppe Cirino, Salvatore Cuzzocrea, Romano Danesi, Monica Di LucaGiorgio Cantelli Forti, Armando Genazzani, Giovan Battista Leproux, Luca Steardo

Research output: Contribution to journalArticlepeer-review


Hypertension is one of the major risk factor able to promote development and progression of several cardiovascular diseases, including left ventricular hypertrophy and dysfunction, myocardial infarction, stroke, and congestive heart failure. Also, it is one of the major driven of high cardiovascular risk profile in patients with metabolic complications, including obesity, metabolic syndrome and diabetes, as well as in those with renal disease. Thus, effective control of hypertension is a key factor for any preventing strategy aimed at reducing the burden of hypertension-related cardiovascular diseases in the clinical practice. Among various regulatory and contra-regulatory systems involved in the pathogenesis of cardiovascular and renal diseases, renin-angiotensin system (RAS) plays a major role. However, despite the identification of renin and the availability of various assays for measuring its plasma activity, the specific pathophysiological role of RAS has not yet fully characterized. In the last years, however, several notions on the RAS have been improved by the results of large, randomized clinical trials, performed in different clinical settings and in different populations treated with RAS inhibiting drugs, including angiotensin converting enzyme (ACE) inhibitors and antagonists of the AT1 receptor for angiotensin II (ARBs). These findings suggest that the RAS should be considered to have a central role in the pathogenesis of different cardiovascular diseases, for both therapeutic and preventive purposes, without having to measure its level of activation in each patient. The present document will discuss the most critical issues of the pathogenesis of different cardiovascular diseases with a specific focus on RAS blocking agents, including ACE inhibitors and ARBs, in the light of the most recent evidence supporting the use of these drugs in the clinical management of hypertension and hypertension-related cardiovascular diseases.

Original languageEnglish
Pages (from-to)429-444
Number of pages16
JournalHigh Blood Pressure and Cardiovascular Prevention
Issue number4
Publication statusPublished - Dec 1 2015


  • Angiotensin converting enzyme inhibitors
  • Angiotensin receptor blockers
  • Cardiovascular diseases
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Renal disease
  • Renin-angiotensin system
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine


Dive into the research topics of 'Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues'. Together they form a unique fingerprint.

Cite this